Document is current
Any future updates will be listed below
-
Authors
Hutchings, E. D. https://orcid.org/0009-0007-4534-7170
Sawiak, S. J. https://orcid.org/0000-0003-4210-9816
Smith, R. L.
Bethlehem, R. A. I. https://orcid.org/0000-0002-0714-0685
Roberts, A. C. https://orcid.org/0000-0003-2873-157X
Bullmore, E. T.
-
Funding
Funding for this research was provided by:
Rosetrees Trust (MB2023\100002)
- License Information
-
More Information
Article History
Received: 5 November 2025
Accepted: 6 May 2026
First Online: 19 May 2026
Competing interests
: The authors declare the following competing interests: E.T.B. has recently consulted Boehringer Ingelheim, SR One, Novartis, GlaxoSmithKline, Sosei Heptares, and Monument Therapeutics. R.A.I.B. and E.T.B. hold equity in and are cofounders of Centile Bioscience Inc. All other authors declare no competing interests.
